No stone unturned in UK PPRS negotiations
This article was originally published in Scrip
The UK department of healthis leaving no stone unturned during its negotiations on a new pharmaceutical price regulation scheme. It has written to NHS Trusts to gather information on medicines dispensed at home although prescribed in secondary care (hospitals). These products may have bypassed the pharmacy information systems which are being used to collect information on drug prescribing in hospitals. The growth of medicines expenditure in secondary care is significantly higher than in community care, the department points out. It also notes that the headline agreement with the industry signed in June called for a price cut of 2% for medicines if the actual rate of growth in the drugs bill in primary and secondary care in England exceeds 6.7% in either 2008 or in 2009. As the NHS branded drugs bill in primary and secondary care currently stands at £8 billion, the savings the government would get if this additional 2% is triggered would be substantial, the DoH comments.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Merck KGaA’s pharmaceutical sales were adversely affected by the COVID-19 pandemic in the second quarter, but the Process Solutions part of its life sciences division, products from which support vaccine developers, had a good quarter, and a potential dual Toll-like receptor inhibitor, M5049, entered Phase II.
Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.